TW200836724A - Novel compounds - Google Patents

Novel compounds Download PDF

Info

Publication number: TW200836724A
Authority: TW; Taiwan
Prior art keywords: compound; group; mmol; doc; etoac
Prior art date: 2006-09-22

Application number

TW096135178A

Other languages

English (en)

Chinese (zh)

Inventor

Paul Bamborough

Michael David Barker

Sebastien Andre Campos

Richard Peter Charles Cousins

Paul Faulder

Heather Hobbs

Duncan Stuart Holmes

Michael John Johnston

John Liddle

Jeremy John Payne

John Martin Pritchard

Caroline Whitworth

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-22

Filing date

2007-09-20

Publication date

2008-09-16

2006-09-22 Priority claimed from GB0618776A external-priority patent/GB0618776D0/en

2007-03-01 Priority claimed from GB0704012A external-priority patent/GB0704012D0/en

2007-09-04 Priority claimed from GB0717170A external-priority patent/GB0717170D0/en

2007-09-20 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2008-09-16 Publication of TW200836724A publication Critical patent/TW200836724A/zh

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Obesity (AREA)
Dermatology (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Virology (AREA)
Pain & Pain Management (AREA)
Otolaryngology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)

TW096135178A 2006-09-22 2007-09-20 Novel compounds TW200836724A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0618776A GB0618776D0 (en)	2006-09-22	2006-09-22	Novel compounds
GB0704012A GB0704012D0 (en)	2007-03-01	2007-03-01	Novel compounds
GB0717170A GB0717170D0 (en)	2007-09-04	2007-09-04	Novelcompounds

Publications (1)

Publication Number	Publication Date
TW200836724A true TW200836724A (en)	2008-09-16

Family

ID=39092148

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW096135178A TW200836724A (en)	2006-09-22	2007-09-20	Novel compounds

Country Status (11)

Country	Link
US (3)	US20080146606A1 (2)
EP (1)	EP2069341B1 (2)
JP (1)	JP2010504301A (2)
AR (1)	AR062928A1 (2)
AT (1)	ATE493411T1 (2)
CL (1)	CL2007002708A1 (2)
DE (1)	DE602007011645D1 (2)
PE (1)	PE20080925A1 (2)
TW (1)	TW200836724A (2)
UY (1)	UY30600A1 (2)
WO (1)	WO2008034860A1 (2)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0400895D0 (en) *	2004-01-15	2004-02-18	Smithkline Beecham Corp	Chemical compounds
AR050253A1 (es) *	2004-06-24	2006-10-11	Smithkline Beecham Corp	Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
US8063071B2 (en) *	2007-10-31	2011-11-22	GlaxoSmithKline, LLC	Chemical compounds
PE20081889A1 (es)	2007-03-23	2009-03-05	Smithkline Beecham Corp	Indol carboxamidas como inhibidores de ikk2
GB0804592D0 (en) *	2008-03-12	2008-04-16	Glaxo Group Ltd	Novel compounds
GB0804591D0 (en) *	2008-03-12	2008-04-16	Glaxo Group Ltd	Novel compounds
WO2010025236A1 (en) *	2008-08-27	2010-03-04	Alexander Goldin	Composition and method for treating colds
WO2010102968A1 (en)	2009-03-10	2010-09-16	Glaxo Group Limited	Indole derivatives as ikk2 inhibitors
US8754114B2 (en)	2010-12-22	2014-06-17	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
EP2717694A4 (en) *	2011-06-10	2014-11-12	Glaxosmithkline Intellectual Property Ltd	NEW COMPOUNDS
ES2704744T3 (es)	2012-06-13	2019-03-19	Incyte Holdings Corp	Compuestos tricíclicos sustituidos como inhibidores de FGFR
US9388185B2 (en)	2012-08-10	2016-07-12	Incyte Holdings Corporation	Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
US9073922B2 (en) *	2013-03-14	2015-07-07	Abbvie, Inc.	Pyrrolo[2,3-B]pyridine CDK9 kinase inhibitors
MX2015012899A (es) *	2013-03-14	2016-06-02	Abbvie Inc	Pirrolo [2,3-b] piridina como inhibidores de quinasa cdk9.
EA035095B1 (ru)	2013-04-19	2020-04-27	Инсайт Холдингс Корпорейшн	Бициклические гетероциклы в качестве ингибиторов fgfr
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
WO2016134294A1 (en)	2015-02-20	2016-08-25	Incyte Corporation	Bicyclic heterocycles as fgfr4 inhibitors
MX373169B (es)	2015-02-20	2020-04-24	Incyte Holdings Corp	Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CR20200590A (es)	2018-05-04	2021-04-26	Incyte Corp	Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
MA52493A (fr)	2018-05-04	2021-03-10	Incyte Corp	Sels d'un inhibiteur de fgfr
WO2020185532A1 (en)	2019-03-08	2020-09-17	Incyte Corporation	Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en)	2019-07-09	2021-01-14	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en)	2019-10-01	2021-04-08	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
TWI891666B (zh)	2019-10-14	2025-08-01	美商英塞特公司	作為ｆｇｆｒ抑制劑之雙環雜環
WO2021076728A1 (en)	2019-10-16	2021-04-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
BR112022010664A2 (pt)	2019-12-04	2022-08-16	Incyte Corp	Derivados de um inibidor de fgfr
EP4069696A1 (en)	2019-12-04	2022-10-12	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en)	2020-01-15	2021-07-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
TW202304459A (zh)	2021-04-12	2023-02-01	美商英塞特公司	包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
EP4352059A1 (en)	2021-06-09	2024-04-17	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
WO2022261159A1 (en)	2021-06-09	2022-12-15	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
CN114210133B (zh) *	2021-12-13	2023-01-24	广德辉龙环保科技有限公司	一种抗紫外线过滤袋及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR0212613A (pt) *	2001-09-19	2004-08-31	Pharmacia Corp	Compostos de indazol substituìdos para o tratamento de inflamação
GB0308466D0 (en) *	2003-04-11	2003-05-21	Novartis Ag	Organic compounds

2007
- 2007-09-20 AT AT07820377T patent/ATE493411T1/de not_active IP Right Cessation
- 2007-09-20 WO PCT/EP2007/059933 patent/WO2008034860A1/en not_active Ceased
- 2007-09-20 CL CL200702708A patent/CL2007002708A1/es unknown
- 2007-09-20 TW TW096135178A patent/TW200836724A/zh unknown
- 2007-09-20 AR ARP070104169A patent/AR062928A1/es not_active Application Discontinuation
- 2007-09-20 JP JP2009528719A patent/JP2010504301A/ja active Pending
- 2007-09-20 EP EP07820377A patent/EP2069341B1/en active Active
- 2007-09-20 UY UY30600A patent/UY30600A1/es unknown
- 2007-09-20 PE PE2007001270A patent/PE20080925A1/es not_active Application Discontinuation
- 2007-09-20 DE DE602007011645T patent/DE602007011645D1/de active Active
- 2007-09-20 US US11/858,143 patent/US20080146606A1/en not_active Abandoned
- 2007-09-20 US US12/442,012 patent/US20100035917A1/en not_active Abandoned
- 2007-09-20 US US11/858,144 patent/US20080176891A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2008034860A1 (en)	2008-03-27
PE20080925A1 (es)	2008-09-04
US20080176891A1 (en)	2008-07-24
DE602007011645D1 (de)	2011-02-10
EP2069341B1 (en)	2010-12-29
AR062928A1 (es)	2008-12-17
CL2007002708A1 (es)	2008-04-04
JP2010504301A (ja)	2010-02-12
EP2069341A1 (en)	2009-06-17
ATE493411T1 (de)	2011-01-15
US20080146606A1 (en)	2008-06-19
US20100035917A1 (en)	2010-02-11
UY30600A1 (es)	2008-05-02

Publication	Publication Date	Title
TW200836724A (en)	2008-09-16	Novel compounds
CN102203101B (zh)	2014-12-03	作为p38激酶抑制剂的吡咯并[2,3-c]吡啶衍生物
CN104202984B (zh)	2017-04-05	Wnt信号通路的吲唑抑制剂及其治疗应用
CN104684915B (zh)	2017-10-31	新型双环衍生物
CN110183440B (zh)	2022-04-22	杂芳基syk抑制剂
JP5876051B2 (ja)	2016-03-02	インフルエンザウィルス感染の治療に使用するためのインダゾール誘導体
EP2683710B1 (en)	2017-07-19	Soluble guanylate cyclase activators
TWI309165B (en)	2009-05-01	Novel morpholine compounds
JP2010529002A (ja)	2010-08-26	ピロロピリジン化合物、その調製方法、および医薬としてのその使用
CA2877474A1 (en)	2012-12-27	Compounds and therapeutic uses thereof
TW201103927A (en)	2011-02-01	Novel compounds
TW201000460A (en)	2010-01-01	Amide compound
CN104513235B (zh)	2017-12-05	取代的氨基嘧啶类化合物及其使用方法和用途
CN104271133A (zh)	2015-01-07	1H-吡唑并[3,4-b]吡啶及其治疗应用
CN102791697A (zh)	2012-11-21	作为TBKL和/或IKKε抑制剂的氨基-嘧啶化合物
TW200927104A (en)	2009-07-01	Azaindoles useful as inhibitors of JAK and other protein kinases
CN104995172A (zh)	2015-10-21	Trk抑制化合物
BR112015004529B1 (pt)	2022-06-21	Alcóxi pirazóis, seu uso como ativadores de guanilato ciclase solúvel e composição farmacêutica que os compreende
TW200811169A (en)	2008-03-01	Chemical compounds
TW200811116A (en)	2008-03-01	Compounds
TWI425945B (zh)	2014-02-11	四氫異喹啉－１－酮衍生物或其鹽
CN115052604A (zh)	2022-09-13	Masp-2抑制剂和使用方法
CN111566102A (zh)	2020-08-21	作为激活素受体样激酶抑制剂的取代的吡咯并吡啶
TW200922581A (en)	2009-06-01	Compounds
TW201024298A (en)	2010-07-01	(R)-3-(N,N-dimethylamino)pyrrolidine derivatives